Dynamics of Islet Autoantibodies During Prospective Follow-Up From Birth to Age 15 Years
- PMID: 32882033
- PMCID: PMC7686032
- DOI: 10.1210/clinem/dgaa624
Dynamics of Islet Autoantibodies During Prospective Follow-Up From Birth to Age 15 Years
Abstract
Context: We set out to characterize the dynamics of islet autoantibodies over the first 15 years of life in children carrying genetic susceptibility to type 1 diabetes (T1D). We also assessed systematically the role of zinc transporter 8 autoantibodies (ZnT8A) in this context.
Design: HLA-predisposed children (N = 1006, 53.0% boys) recruited from the general population during 1994 to 1997 were observed from birth over a median time of 14.9 years (range, 1.9-15.5 years) for ZnT8A, islet cell (ICA), insulin (IAA), glutamate decarboxylase (GADA), and islet antigen-2 (IA-2A) antibodies, and for T1D.
Results: By age 15.5 years, 35 (3.5%) children had progressed to T1D. Islet autoimmunity developed in 275 (27.3%) children at a median age of 7.4 years (range, 0.3-15.1 years). The ICA seroconversion rate increased toward puberty, but the biochemically defined autoantibodies peaked at a young age. Before age 2 years, ZnT8A and IAA appeared commonly as the first autoantibody, but in the preschool years IA-2A- and especially GADA-initiated autoimmunity increased. Thereafter, GADA-positive seroconversions continued to appear steadily until ages 10 to 15 years. Inverse IAA seroconversions occurred frequently (49.3% turned negative) and marked a prolonged delay from seroconversion to diagnosis compared to persistent IAA (8.2 vs 3.4 years; P = .01).
Conclusions: In HLA-predisposed children, the primary autoantibody is characteristic of age and might reflect the events driving the disease process toward clinical T1D. Autoantibody persistence affects the risk of T1D. These findings provide a framework for identifying disease subpopulations and for personalizing the efforts to predict and prevent T1D.
Keywords: HLA; children; dynamics; islet autoantibodies; prediction; type 1 diabetes.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Figures
Comment in
-
Birth Cohorts in Type 1 Diabetes: Preparing for the Payoff.J Clin Endocrinol Metab. 2021 Jan 23;106(2):e1044-e1045. doi: 10.1210/clinem/dgaa736. J Clin Endocrinol Metab. 2021. PMID: 33159437 No abstract available.
Similar articles
-
Characterisation of rapid progressors to type 1 diabetes among children with HLA-conferred disease susceptibility.Diabetologia. 2017 Jul;60(7):1284-1293. doi: 10.1007/s00125-017-4258-7. Epub 2017 Mar 31. Diabetologia. 2017. PMID: 28364254
-
Hierarchical Order of Distinct Autoantibody Spreading and Progression to Type 1 Diabetes in the TEDDY Study.Diabetes Care. 2020 Sep;43(9):2066-2073. doi: 10.2337/dc19-2547. Epub 2020 Jul 8. Diabetes Care. 2020. PMID: 32641373 Free PMC article.
-
Childhood thyroid autoimmunity and relation to islet autoantibodies in children at risk for type 1 diabetes in the diabetes prediction in skåne (DiPiS) study.Autoimmunity. 2018 Aug;51(5):228-237. doi: 10.1080/08916934.2018.1519027. Autoimmunity. 2018. PMID: 30486698
-
Possible heterogeneity of initial pancreatic islet beta-cell autoimmunity heralding type 1 diabetes.J Intern Med. 2023 Aug;294(2):145-158. doi: 10.1111/joim.13648. Epub 2023 May 14. J Intern Med. 2023. PMID: 37143363 Free PMC article. Review.
-
Humoral beta-cell autoimmunity in relation to HLA-defined disease susceptibility in preclinical and clinical type 1 diabetes.Am J Med Genet. 2002 May 30;115(1):48-54. doi: 10.1002/ajmg.10343. Am J Med Genet. 2002. PMID: 12116176 Review.
Cited by
-
Mechanisms underlying the development of type 1 diabetes in ART-treated people living with HIV: an enigmatic puzzle.Front Immunol. 2024 Aug 27;15:1470308. doi: 10.3389/fimmu.2024.1470308. eCollection 2024. Front Immunol. 2024. PMID: 39257582 Free PMC article. Review.
-
Estimation of Individual Positive Anti-Islet Autoantibodies from 3 Screen ICA Titer.Int J Mol Sci. 2024 Jul 11;25(14):7618. doi: 10.3390/ijms25147618. Int J Mol Sci. 2024. PMID: 39062856 Free PMC article.
-
Factors Governing B Cell Recognition of Autoantigen and Function in Type 1 Diabetes.Antibodies (Basel). 2024 Apr 1;13(2):27. doi: 10.3390/antib13020027. Antibodies (Basel). 2024. PMID: 38651407 Free PMC article. Review.
-
Islet autoantibodies as precision diagnostic tools to characterize heterogeneity in type 1 diabetes: a systematic review.Commun Med (Lond). 2024 Apr 6;4(1):66. doi: 10.1038/s43856-024-00478-y. Commun Med (Lond). 2024. PMID: 38582818 Free PMC article.
-
Teplizumab in Type 1 Diabetes Mellitus: An Updated Review.touchREV Endocrinol. 2023 Nov;19(2):22-30. doi: 10.17925/EE.2023.19.2.7. Epub 2023 Oct 6. touchREV Endocrinol. 2023. PMID: 38187075 Free PMC article. Review.
References
-
- Knip M, Siljander H. Autoimmune mechanisms in type 1 diabetes. Autoimmun Rev. 2008;7(7):550-557. - PubMed
-
- Parikka V, Näntö-Salonen K, Saarinen M, et al. Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia. 2012;55(7):1926-1936. - PubMed
-
- Schlosser M, Koczwara K, Kenk H, et al. In insulin-autoantibody-positive children from the general population, antibody affinity identifies those at high and low risk. Diabetologia. 2005;48(9):1830-1832. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous